D. A. Evseev

ORCID: 0000-0001-8610-0624
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Photonic Crystals and Applications
  • Histiocytic Disorders and Treatments
  • Acute Myeloid Leukemia Research
  • Plasmonic and Surface Plasmon Research
  • Acute Lymphoblastic Leukemia research
  • Viral-associated cancers and disorders
  • Neutropenia and Cancer Infections
  • Vascular Malformations and Hemangiomas
  • Health and Conflict Studies
  • Thermal Radiation and Cooling Technologies
  • Graphene research and applications
  • Metamaterials and Metasurfaces Applications
  • Hematopoietic Stem Cell Transplantation
  • Immunotherapy and Immune Responses
  • Retinoids in leukemia and cellular processes
  • Tumors and Oncological Cases
  • Hydrogen embrittlement and corrosion behaviors in metals
  • Engineering Technology and Methodologies
  • Microstructure and Mechanical Properties of Steels
  • Near-Field Optical Microscopy
  • Parvovirus B19 Infection Studies
  • Migration, Health and Trauma
  • Gold and Silver Nanoparticles Synthesis and Applications
  • Blood disorders and treatments
  • Platelet Disorders and Treatments

Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2019-2024

Ministry of Health of the Russian Federation
2021-2024

Russian University of Transport
2024

St. Jude Children's Research Hospital
2023-2024

Ulyanovsk State University
2014-2023

PURPOSE Off-label use of vemurafenib (VMF) to treat BRAF V600E mutation–positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses Disease Activity Score. RESULTS...

10.1200/jco.19.00456 article EN cc-by-nc-nd Journal of Clinical Oncology 2019-09-12

Abstract ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented case reports series to occupy wider clinicopathologic spectrum recurrent KIF5B-ALK fusions. The full molecular spectra remain, however, poorly characterized. Here, we describe largest study date, detailed data 39 cases, including 37 cases confirmed ALK...

10.1182/blood.2021013338 article EN cc-by Blood 2021-11-02

We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) IST alone in treatment-naïve children severe (SAA) very (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) cyclosporin A (CsA) (n = 49) or without ELTR. The primary endpoint was overall response rate (ORR) at 4 months. After months, nonresponders crossed over alternative group. In all patients, ORR ELTR + groups similar...

10.1182/bloodadvances.2021006716 article EN cc-by-nc-nd Blood Advances 2022-04-21

Langerhans cell histiocytosis (LCH) is a disorder with variety of clinical signs. The most severe forms affect risk organs (RO). established role the BRAF V600E mutation in LCH led to targeted approach. However, therapy cannot cure disease, and cessation leads quick relapses. Here, we combined cytosine-arabinoside (Ara-C) 2'-chlorodeoxyadenosine (2-CdA) achieve stable remission. Nineteen children were enrolled study: 13 RO-positive (RO+) 6 RO-negative (RO-). Five patients received upfront,...

10.1182/bloodadvances.2022009067 article EN cc-by-nc-nd Blood Advances 2023-05-22
Marta Salek Alexandra S. Mueller Inna Alanbousi Zuzanna Paulina Cepowska Małgorzata Dutkiewicz and 95 more Julian Darocus Earl D. A. Evseev Roman Kizyma Khrystyna Kliuchkivska Julia Kołodrubiec K. Matczak Yuliya Nogovitsyna Aleksandra Oszer Mikhail V. Pogorelyy Anna Raciborska Suheir Subhi Rasul Igor Sokołowski Andriy Sopilnyak Anna Vinitsky Marcin W. Włodarski Natalia Margarete Wobst Taisiya Yakimkova Carlos Rodríguez‐Galindo Paul H. Wise Wojciech Młynarski Asya Agulnik Sarah Weeks Alexander Anna Apel Mykhaylo V Adyrov Meghana Avula Wioletta Bal Walentyna Aniela Balwierz Luisa Basset‐Salom Daniel Bastardo Blanco Karolina Jadwiga Bauer Ildar T. Bayazitov Pablo Berlanga Nickhill Hitesh Bhakta Katarzyna Anna Bieniek Ewa Iwona Bien Christopher Andrew Blackwood Sally Jane Blair Khrystyna Ihorivna Bodak Irina Michael Bordeianu Éric Bouffet Joao Maria Braganca Mihaela Silvia Bucurenci Elżbieta Beata Budny Andrii Budzyn Christopher Carl Bumgardner Raina Nichole Burditt Victoria Burnside Clapp Viacheslav Valeriyovych Bykov Adela Cañete Monica Carnelli Elena Cela Radosław Chaber Anna Cherner-Drieux Mariya Chubata Heidi M Clough Piotr Stefan Czauderna Jolanta Czernicka - Siwecka K Czyźewski Jean‐Hugues Dalle Olha Dashchakovska Linda A de Koning Bozenna Malgorzata Dembowska-Baginska Katarzyna Derwich Uta Dirksen Rachel Dommett О.І. Дорош Nuno Jorge Farinha Katarzyna Anna Drabko Monica Dragomir Michael Dworzak Sergii Vitaliiovych Dyma Angelika Eggert Martin English Becky S Farren Nataliia Yuriina Fedyk Ana Fernández‐Teijeiro Severyn Ferneza Whitney Baer Foster Leeanna Elizabeth Fox Irwin Robert Maciej Gałązkowski Galyna Ganieva Vasylyna Andriivna Garanzha Marina S. Gelman Jan Krzysztof Godzinski Anne Françoise Goeres Rodica Golban Dylan Elizabeth Graetz Jeanette Greiner Michael Griksaitis Sumit Gupta Michal Andrzej Hampel Sara Grace Hastings Delphine Liliane Heenen Marcela C Hill Ihor Holiuk

10.1016/s1470-2045(23)00456-4 article EN The Lancet Oncology 2023-11-28
Asya Agulnik Roman Kizyma Marta Salek Marcin W. Włodarski Mikhail V. Pogorelyy and 95 more Aleksandra Oszer Taisiya Yakimkova Yuliya Nogovitsyna Małgorzata Dutkiewicz Jean‐Hugues Dalle Uta Dirksen Angelika Eggert Ana Fernández‐Teijeiro Jeanette Greiner Kathelijne C.J.M. Kraal Alexandra S. Mueller Lucie Šrámková Marco Zecca Paul H. Wise Wojciech Młynarski Meghana Avula Mykhaylo V Adyrov Pablo Berlanga Christopher Andrew Blackwood Éric Bouffet Piotr Stefan Czauderna Linda A de Koning Nuno Jorge Farinha Whitney Baer Foster Dylan Elizabeth Graetz Sumit Gupta Wolfgang Holter Rachael Hough Khrystyna Kliuchkivska Alexandra Kolenová Julia Kołodrubiec Daniel C. Moreira Sheena Teresa Mukkada Iryna Volodymyrivna Mykychak Anna Raciborska Zeena S Salman Andriy Sopilnyak Sergiy Ihorovych Tyupa Anna Vinitsky Natalia Margarete Wobst Beth Anne Miller Suheir Subhi Rasul Carlos Rodríguez‐Galindo Inna Alanbousi Sarah Weeks Alexander Anna Apel Wioletta Bal Walentyna Aniela Balwierz Luisa Basset‐Salom Daniel Bastardo Blanco Karolina Jadwiga Bauer Ildar T. Bayazitov Nickhill Hitesh Bhakta Ewa Iwona Bien Katarzyna Anna Bieniek Sally Jane Blair Khrystyna Ihorivna Bodak Irina Michael Bordeianu Joao Maria Braganca Mihaela Silvia Bucurenci Elżbieta Beata Budny Andrii Budzyn Christopher Carl Bumgardner Raina Nichole Burditt Victoria Grace Burnside Clapp Viacheslav Valeriyovych Bykov Adela Cañete Monica Carnelli Elena Cela Zuzanna Paulina Cepowska Radosław Chaber Anna Cherner-Drieux Mariya Chubata Heidi M Clough Jolanta Czernicka - Siwecka K Czyźewski Olha Dashchakovska Bozenna Malgorzata Dembowska-Baginska Katarzyna Derwich Rachel Dommett О.І. Дорош Katarzyna Anna Drabko Monica Dragomir Michael Dworzak Sergii Vitaliiovych Dyma Julian Darocus Earl Martin English D. A. Evseev Becky S Farren Nataliia Yuriina Fedyk Severyn Ferneza Leeanna Elizabeth Fox Irwin Robert Maciej Gałązkowski Galyna Ganieva Vasylyna Andriivna Garanzha

10.1016/s2352-3026(22)00259-9 article EN The Lancet Haematology 2022-08-30

A theoretical study of the plasmon modes’ characteristics is carried out in a structure consisting two active graphene layers separated by dielectric barrier layer. general dispersion relation obtained, numerical analysis which reveals possibility controlling parameters amplified surface modes region negative conductivity. In particular, their controlled changing chemical potential layers. For antisymmetric plasmons, dependence on layer was revealed. An increase makes it possible to expand...

10.3390/photonics9080587 article EN cc-by Photonics 2022-08-19

Novel van der Waals heterostructures from graphenylene and 2D 1H-MoX<sub>2</sub>(X = S, Te, Se) monolayers are analyzed using<italic>ab initio</italic>calculations. They stable under normal conditions exhibit optical absorption across the entire visible range.

10.1039/d1cp01062j article EN Physical Chemistry Chemical Physics 2021-01-01

The features of the guided TE modes propagation have been investigated on basis computer simulations in a planar structure consisting set alternating layers dielectric and graphene. Within framework effective medium approximation, dispersion relations received for symmetric antisymmetric waveguide modes, determined by frequency range their existence. wave field distribution structure, dependences constants transverse components vectors, as well group phase velocities obtained, effect...

10.1051/epjap/2017170167 article EN The European Physical Journal Applied Physics 2017-10-01

Abstract Immune thrombocytopenia (ITP) is believed to be associated with platelet function defects. However, their mechanisms are poorly understood, in particular regard differences between ITP phases, patient age, and therapy. We investigated bleeding children either persistent or chronic ITP, without romiplostim The study included 151 of whom 56 had disease duration less than 12 months (grouped together as acute/persistent) 95 were chronic. Samples 57 healthy used controls, while 5...

10.1038/s41598-021-88900-6 article EN cc-by Scientific Reports 2021-04-30

Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification various secondary molecular genetic events can facilitate JMML progression and transformation into acute myeloid (sAML). The methods single-cell DNA (scDNA-seq) enable overcoming limitations bulk NGS exploring heterogeneity at level individual cells, which help...

10.1038/s41540-023-00303-7 article EN cc-by npj Systems Biology and Applications 2023-09-09

Over the past years, outcomes of patients with acute myeloid leukemia (AML) have significantly improved due to use intensive chemotherapy, more effective supportive therapy, and availability allogeneic hematopoietic stem cell transplantation. This article presents children AML treated in accordance AML-MM-2006 protocol. Our study was approved by Independent Ethics Committee Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology. The included 233 a median...

10.24287/1726-1708-2022-21-1-20-35 article EN cc-by Pediatric Hematology/Oncology and Immunopathology 2022-03-27

Background. Langerhans cell histiocytosis (LCH) is a rare disease that occurs due to abnormal proliferation and expansion of myeloid precursors. The occurrence mutations in genes encode key kinases MAPK-signaling pathway leads its pathological activation has been shown the cause disease. Mutations BRAF MAP2K1 are most frequent among LCH patients. effectiveness BRAF-inhibitors patients numerous studies. purpose study – analyze experience BRAF-inhibitor vemurafenib administration as...

10.21682/2311-1267-2023-10-4-13-24 article EN Russian Journal of Pediatric Hematology and Oncology 2024-01-16

A technique to find out the remaining service life of a passenger car based on statistical data failures elements is considered and described.&#x0D; The regulatory many cars coming an end, therefore it becomes necessary actual before its decommissioning disposal.

10.30987/2782-5957-2024-2-56-61 article EN Transport engineering 2024-02-14

The study objective is to consider main risks that arise during operation of a passenger train. Integration various regulatory bases into single analytical base for each unit rolling stock, followed by the formation their digital twin with possibility automatic residual life, risk map equipment failure, cost analysis and reduction its distraction in an idle fleet.

10.30987/2782-5957-2024-3-49-58 article EN Transport engineering 2024-03-13
Coming Soon ...